368 related articles for article (PubMed ID: 31725451)
1. Generation and application of patient-derived xenograft models in pancreatic cancer research.
Wang CF; Shi XJ
Chin Med J (Engl); 2019 Nov; 132(22):2729-2736. PubMed ID: 31725451
[TBL] [Abstract][Full Text] [Related]
2. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
Allaway RJ; Fischer DA; de Abreu FB; Gardner TB; Gordon SR; Barth RJ; Colacchio TA; Wood M; Kacsoh BZ; Bouley SJ; Cui J; Hamilton J; Choi JA; Lange JT; Peterson JD; Padmanabhan V; Tomlinson CR; Tsongalis GJ; Suriawinata AA; Greene CS; Sanchez Y; Smith KD
Oncotarget; 2016 Mar; 7(13):17087-102. PubMed ID: 26934555
[TBL] [Abstract][Full Text] [Related]
3. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
4. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
Sereti E; Karagianellou T; Kotsoni I; Magouliotis D; Kamposioras K; Ulukaya E; Sakellaridis N; Zacharoulis D; Dimas K
J Proteomics; 2018 Sep; 188():107-118. PubMed ID: 29398619
[TBL] [Abstract][Full Text] [Related]
5. A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma.
Ozaki M; Kageyama K; Kimura K; Eguchi S; Yamamoto A; Tanaka R; Nota T; Yonezawa H; Nishiofuku H; Sakai Y; Tani N; Jogo A; Terai M; Sato T; Ishizawa T; Miki Y
Sci Rep; 2024 May; 14(1):10529. PubMed ID: 38719893
[TBL] [Abstract][Full Text] [Related]
6. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer.
Wang Y; Cui J; Wang L
Chin Clin Oncol; 2019 Apr; 8(2):17. PubMed ID: 30943729
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a Liver Transplant Patient-derived Tumor Xenograft (PDX) Model Using Cryopreserved Pancreatic Ductal Adenocarcinoma.
Tanaka R; Kageyama K; Kimura K; Eguchi S; Tauchi J; Shinkawa H; Ohira GO; Yamazoe S; Yamamoto A; Tanaka S; Amano R; Tanaka H; Yashiro M; Kubo S; Ohira M
Anticancer Res; 2020 May; 40(5):2637-2644. PubMed ID: 32366408
[TBL] [Abstract][Full Text] [Related]
10. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine.
Gerber MH; Underwood PW; Judge SM; Delitto D; Delitto AE; Nosacka RL; DiVita BB; Thomas RM; Permuth JB; Hughes SJ; Wallet SM; Judge AR; Trevino JG
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513792
[TBL] [Abstract][Full Text] [Related]
11. Mouse Models of Pancreatic Ductal Adenocarcinoma.
Ponz-Sarvise M; Tuveson DA; Yu KH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
[TBL] [Abstract][Full Text] [Related]
12. PDX-derived organoids model in vivo drug response and secrete biomarkers.
Huang L; Bockorny B; Paul I; Akshinthala D; Frappart PO; Gandarilla O; Bose A; Sanchez-Gonzalez V; Rouse EE; Lehoux SD; Pandell N; Lim CM; Clohessy JG; Grossman J; Gonzalez R; Del Pino SP; Daaboul G; Sawhney MS; Freedman SD; Kleger A; Cummings RD; Emili A; Muthuswamy LB; Hidalgo M; Muthuswamy SK
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990680
[TBL] [Abstract][Full Text] [Related]
13. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
15. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
Witkiewicz AK; Balaji U; Eslinger C; McMillan E; Conway W; Posner B; Mills GB; O'Reilly EM; Knudsen ES
Cell Rep; 2016 Aug; 16(7):2017-31. PubMed ID: 27498862
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
[TBL] [Abstract][Full Text] [Related]
17. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival.
Pergolini I; Morales-Oyarvide V; Mino-Kenudson M; Honselmann KC; Rosenbaum MW; Nahar S; Kem M; Ferrone CR; Lillemoe KD; Bardeesy N; Ryan DP; Thayer SP; Warshaw AL; Fernández-Del Castillo C; Liss AS
PLoS One; 2017; 12(8):e0182855. PubMed ID: 28854237
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived xenograft models of BRCA-associated pancreatic cancers.
Golan T; Atias D; Stossel C; Raitses-Gurevich M
Adv Drug Deliv Rev; 2021 Apr; 171():257-265. PubMed ID: 33617901
[TBL] [Abstract][Full Text] [Related]
19. Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor.
Wen S; Lin X; Luo W; Pan Y; Liao F; Wang Z; Zhan B; Feng J; Huang H
BMC Cancer; 2024 Apr; 24(1):485. PubMed ID: 38632504
[TBL] [Abstract][Full Text] [Related]
20. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma.
Liu Z; Ahn MH; Kurokawa T; Ly A; Zhang G; Wang F; Yamada T; Sadagopan A; Cheng J; Ferrone CR; Liss AS; Honselmann KC; Wojtkiewicz GR; Ferrone S; Wang X
J Transl Med; 2020 Jun; 18(1):255. PubMed ID: 32580742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
